Skip to main content

Maria Mar Hernandez Guillamon

Institutions of which they are part

Senior researcher
Neurovascular Diseases
Vall Hebron Institut de Recerca

Research lines

L5 Cerebral Amyloid Angiopathy

Current project: Involment of proteolytic systems in the progression of Cerebral Amyloid Angiopathy Cerebral amyloid angiopathy (CAA) is produced by the accumulation of ß-amyloid protein within the meningeal and brain vessels. It is the second leading cause of cerebral hemorrhages. However, nowadays, factors related to brain bleedings following amyloid deposition are largely unknown. The understanding of the mollecular mechanisms that lead to cerebral hemorrhage may be the basis for future treatments. Previous evidences of our group have shown that Matrix Metal•loproteinases (MMPs) are related to brain bleeding. Now, we aim to investigate the relationship between these proteolytic systems and the appearance of intracraneal hemorrages in CAA. Our study includes: 1) The identification of both tissue and plasma biomarkers for the diagnosis and prognosis of CAA-related hemorrhages. 2) The search of the genetic markers related to proteolytic systems that could determine the risk of suffering a recurrence in CAA. We are studying a cohort of probable CAA patients that have been recruited in Hospital Vall d’Hebron in collaboration with the Stroke Project of the Cerebrovascular Diseases Study Group (Spanish Society of Neurology). 3) The study of MMPs role in ß-amyloid stimulated vascular cells in vitro. Cultured cells of the neurovascular unit are challenged with different ß-amyloid peptides and the implication of MMPs in ß-amyloid cleavage and cell toxicity are studied using cellular and molecular biology methodology. For this purpose, we use the human cerebral endothelial cell line hCMEC/D3, primary cultures of human leptomeningeal smooth muscle cells and rat/mouse glial and neuronal cultures. Thioflavin-S staining of fibillar ß-amyloid within brain vessels of CAA patient’s sections. Related bibliography: 1) Hernández-Guillamon M, Delgado P, Ortega L, Pares M, Rosell A, García-Bonilla L, Fernández-Cadenas I, Borrell-Pagès M, Boada M, Montaner J. Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25-35 fragment. J Neurosci Res. 2009 Jul;87(9):2115-25. 2) Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA, Lo EH, Montaner J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006 Jun;37(6):1399-406. 3) Alvarez-Sabín J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M, Santamarina E, Quintana M, Monasterio J, Montaner J. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke. 2004 Jun;35(6):1316-22. 4) Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003 Feb 4;107(4):598-603. Collaborations: Mercè Boada Fundació ACE, Barcelona, Spain. www.fundacioace.com/ Jorge Ghiso and Agueda Rostagno Pathology Dept. Langone Medical Center. NYU New York, US. Ignacio Romero Life Science Dept. Open University. Milton Keynes, UK.

IP: Maria Mar Hernandez Guillamon

Projects

IBCAA Snowball - Image guided non-invasive brain stimulation for safe and therapeutically effective modulation of blood-brain-barrier function and neural networks in cerebral amyloid angiopathy

IP: Maria Mar Hernandez Guillamon
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: CLIENT
Reference: EC/ERANET_JNPD/2020/HERNANDEZ
Duration: -

Implicaction of proteins associated with vascular beta-amyloid in Cerebral Amyloid Angiopathy

IP: Maria Mar Hernandez Guillamon
Collaborators: Marcel Lamana Vallverdu, Anna Bonaterra Pastra, Jessica Camacho Soriano, Olga Maisterra Santos, Montserrat Solé Piñol, Olalla Pancorbo Rosal
Funding agency: Instituto de Salud Carlos III
Funding: 169400
Reference: PI20/00465
Duration: 01/01/2021 - 31/12/2023

Nanotechnology albumin-based approach for the diagnosis and future treatment of Alzheimer's Disease

IP: Maria Mar Hernandez Guillamon
Collaborators: -
Funding agency: Grifols S.A.
Funding: 50000
Reference: GRIFOLS/AAAP/2019-20/HERNANDEZ
Duration: 01/12/2020 - 30/11/2021

Estudio de asociación del genoma completo (GWAS) en pacientes con hemorragia intracerebral.

IP: Maria Mar Hernandez Guillamon
Collaborators: -
Funding agency:
Funding:
Reference: PR(AG)262/2019
Duration: -

Related news

The international study has identified 89 genes involved in the risk of developing a stroke, 61 of which had not been previously described.

Entre els projectes es troben 12 investigacions on participen investigadors i investigadores de Vall d’Hebron.

The international study incorporates new magnetic resonance markers to increase sensitivity in the diagnosis of this disease.

Related professionals

Mara Cruellas Lapeña

Mara Cruellas Lapeña

Predoctoral researcher
Read more
Nadia Puertas  Porrino

Nadia Puertas Porrino

Read more
Coro Bescós Atin

Coro Bescós Atin

Head of group
New Technologies and Craniofacial Microsurgery
Read more
Rosa Mejon Berges

Rosa Mejon Berges

Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.